Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

Authors: Bernell, Per¹; Ohm, Lotta¹

Source: British Journal of Haematology, Volume 101, Number 1, April 1998 , pp. 203-204(2)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Three patients (aged 68-75 years) with histologically confirmed relapsed or refractory high-grade non-Hodgkin's lymphoma were entered in this pilot study in which gemcitabine 800 mg/m² was given as a 30 min i.v. infusion once a week for 3 weeks. One patient responded with complete remission and the other two with partial remission and stable disease for 2 and 3 months, respectively. Haematological toxicity was modest with grade 4 leucopenia (one cycle) and grade 4 thrombocytopenia (two cycles). The activity and mild toxicity seen with gemcitabine suggest that this agent should be further evaluated in the treatment of high-grade non-Hodgkin's lymphoma.

Keywords: gemcitabine; refractory; non-Hodgkin's lymphoma

Document Type: Research article

DOI: 10.1046/j.1365-2141.1998.00667.x

Affiliations: 1: Division of Haematology, Department of Medicine, Karolinska Institute at Danderyd Hospital, Stockholm, Sweden

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy